Display options
Cite
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes. 2011;2(12):217-20doi: 10.4239/wjd.v2.i12.217.
Boj-Carceller, D., Bocos-Terraz, P., Moreno-Vernis, M., Sanz-Paris, A., Trincado-Aznar, P., & Albero-Gamboa, R. (2011). Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World journal of diabetes, 2(12), 217-20. https://doi.org/10.4239/wjd.v2.i12.217
Boj-Carceller, Diana, et al. "Are proton pump inhibitors a new antidiabetic drug? A cross sectional study." World journal of diabetes vol. 2,12 (2011): 217-20. doi: https://doi.org/10.4239/wjd.v2.i12.217
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes. 2011 Dec 15;2(12):217-20. doi: 10.4239/wjd.v2.i12.217. PMID: 22174957; PMCID: PMC3238490.
Copy Download .nbib Format: NLM
Share it on

World J Diabetes. 2011 Dec 15;2(12):217-20. doi: 10.4239/wjd.v2.i12.217.

Are proton pump inhibitors a new antidiabetic drug? A cross sectional study.

World journal of diabetes

Diana Boj-Carceller, Pilar Bocos-Terraz, Miguel Moreno-Vernis, Alejandro Sanz-Paris, Pablo Trincado-Aznar, Ramón Albero-Gamboa

Affiliations

  1. Diana Boj-Carceller, Alejandro Sanz-Paris, Pablo Trincado- Aznar, Ramón Albero-Gamboa, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain.

PMID: 22174957 PMCID: PMC3238490 DOI: 10.4239/wjd.v2.i12.217

Abstract

AIM: To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabetic patients.

METHODS: A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis of hyperglycemic decompensation, diabetic onset or pregnancy. It compared HbA1c levels of those taking PPIs and those not.

RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to -0.83. People who used PPIs with some type of insulin therapy had a HbA1c reduction by -0.8%, 95% CI: -0.12 to -1.48. For the rest of subgroup analysis based on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels.

CONCLUSION: PPIs seems to be consistently associated with better glycemic control in type 2 diabetes. HbA1c reduction observed is similar to incretin-based therapies.

Keywords: Diabetes mellitus; Drug therapy; Hypoglycemic agents; Incretins; Proton pump inhibitors

References

  1. Aliment Pharmacol Ther. 2005 Jul 1;22(1):59-65 - PubMed
  2. Diabetes Care. 2009 Jan;32(1):193-203 - PubMed
  3. J Clin Invest. 1988 Sep;82(3):1059-66 - PubMed
  4. Acta Diabetol. 2009 Jun;46(2):85-95 - PubMed
  5. Dig Dis Sci. 2011 Apr;56(4):931-50 - PubMed
  6. Diabetes Res Clin Pract. 2010 Dec;90(3):e72-4 - PubMed
  7. Am J Med. 2010 Mar;123(3 Suppl):S28-37 - PubMed
  8. J Clin Endocrinol Metab. 2005 Jun;90(6):3401-9 - PubMed
  9. Am J Gastroenterol. 1994 Nov;89(11):2033-7 - PubMed
  10. Curr Opin Gastroenterol. 2010 Nov;26(6):598-603 - PubMed
  11. Endocr Pract. 2010 Sep-Oct;16(5):835-7 - PubMed
  12. Med Hypotheses. 2009 Jul;73(1):29-32 - PubMed
  13. Diabetes. 2002 Mar;51(3):686-90 - PubMed
  14. Dig Dis Sci. 2010 Sep;55(9):2431-40 - PubMed
  15. Diabetes. 2005 Sep;54(9):2596-601 - PubMed

Publication Types